264 related articles for article (PubMed ID: 22213565)
1. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases.
Wang G; Mostafa NZ; Incani V; Kucharski C; Uludağ H
J Biomed Mater Res A; 2012 Mar; 100(3):684-93. PubMed ID: 22213565
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate-derivatized liposomes to control drug release from collagen/hydroxyapatite scaffolds.
Wang G; Babadağli ME; Uludağ H
Mol Pharm; 2011 Aug; 8(4):1025-34. PubMed ID: 21557579
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration.
Wang G; Kucharski C; Lin X; Uludağ H
J Drug Target; 2010 Sep; 18(8):611-26. PubMed ID: 20158316
[TBL] [Abstract][Full Text] [Related]
4. Cleavage of disulfide-linked fetuin-bisphosphonate conjugates with three physiological thiols.
Zhang S; Wright JE; Bansal G; Cho P; Uludag H
Biomacromolecules; 2005; 6(5):2800-8. PubMed ID: 16153121
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
[TBL] [Abstract][Full Text] [Related]
6. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro.
Hengst V; Oussoren C; Kissel T; Storm G
Int J Pharm; 2007 Mar; 331(2):224-7. PubMed ID: 17150316
[TBL] [Abstract][Full Text] [Related]
7. The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite.
Zhang S; Wright JE; Ozber N; Uludağ H
Macromol Biosci; 2007 May; 7(5):656-70. PubMed ID: 17457941
[TBL] [Abstract][Full Text] [Related]
8. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.
Talelli M; Iman M; Varkouhi AK; Rijcken CJ; Schiffelers RM; Etrych T; Ulbrich K; van Nostrum CF; Lammers T; Storm G; Hennink WE
Biomaterials; 2010 Oct; 31(30):7797-804. PubMed ID: 20673684
[TBL] [Abstract][Full Text] [Related]
9. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis.
Doschak MR; Kucharski CM; Wright JE; Zernicke RF; Uludağ H
Mol Pharm; 2009; 6(2):634-40. PubMed ID: 19718808
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles.
Hu FQ; Liu LN; Du YZ; Yuan H
Biomaterials; 2009 Dec; 30(36):6955-63. PubMed ID: 19782395
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
12. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) -- structural investigations on two different carrier systems.
Saupe A; Wissing SA; Lenk A; Schmidt C; Müller RH
Biomed Mater Eng; 2005; 15(5):393-402. PubMed ID: 16179760
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
14. Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis.
Haeri A; Sadeghian S; Rabbani S; Anvari MS; Boroumand MA; Dadashzadeh S
Int J Pharm; 2011 Jul; 414(1-2):16-27. PubMed ID: 21554939
[TBL] [Abstract][Full Text] [Related]
15. Active targeting of brain tumors using nanocarriers.
Béduneau A; Saulnier P; Benoit JP
Biomaterials; 2007 Nov; 28(33):4947-67. PubMed ID: 17716726
[TBL] [Abstract][Full Text] [Related]
16. Archaeosomes as carriers for topical delivery of betamethasone dipropionate: in vitro skin permeation study.
González-Paredes A; Manconi M; Caddeo C; Ramos-Cormenzana A; Monteoliva-Sánchez M; Fadda AM
J Liposome Res; 2010 Dec; 20(4):269-76. PubMed ID: 19954402
[TBL] [Abstract][Full Text] [Related]
17. Targeting glioma cells in vitro with ascorbate-conjugated pharmaceutical nanocarriers.
Salmaso S; Pappalardo JS; Sawant RR; Musacchio T; Rockwell K; Caliceti P; Torchilin VP
Bioconjug Chem; 2009 Dec; 20(12):2348-55. PubMed ID: 19928843
[TBL] [Abstract][Full Text] [Related]
18. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting.
Sawant RR; Torchilin VP
Mol Membr Biol; 2010 Oct; 27(7):232-46. PubMed ID: 20929339
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
20. Nanocarrier possibilities for functional targeting of bioactive peptides and proteins: state-of-the-art.
Moutinho CG; Matos CM; Teixeira JA; Balcão VM
J Drug Target; 2012 Feb; 20(2):114-41. PubMed ID: 22023555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
